Smart! Which one did you go with? Any other top candidates I should look into?
1 Like
Btw., this is useful in many situations. For example, during my recent AFCD surgery, I had a catheter inserted. This abrades the urinary track, and there is some danger of infection. Before surgery I stopped taking empagliflozin, and before I resume taking it again I want to make sure my urinary track is fully healed and there are no bacteria lurking, because obviously, having glucose in your urine can result in unnecessary infections. Therefore before resuming empa in three weeks after surgery I intend to use the strips for a full week to make sure my track is likely free of any infection.
1 Like
Thanks for sharing the info about the test strips!
I didnāt know what AFCD surgery is, so I searched for it.
Is this it?
ACDF (Anterior Cervical Discectomy and Fusion) surgery is a common neck procedure to relieve pain, numbness, or weakness from pinched nerves by removing a damaged spinal disc and fusing the vertebrae together with a bone graft, spacer, and plate/screws, often with high success rates for pain relief and recovery.
Yes, I tend to agree. Iāve been on for a couple of years now and absolutely no issues or noticeable side effects.
3 Likes
Sorry, yes, I meant ACDF, I have a whole thread about it, thatās what Iāll be updating soon.
1 Like
I went from 10mg to 20 mg Jardiance and started severe night time cramps. salt/electrolytes and back down to 10mg. Hopefully this corrects everything.
Our research demonstrated for the first time that EMPA reduced the incidence of ventricular arrhythmia by regulating AMPK/mTOR signaling and restored autophagic flux in DOX-treated rats and NRVCMs.
5 Likes
I donāt have time to read the full paper this morning, but wanted to post this so I donāt forget.
Compared with DPP4i users, SGLT2i users had less cardiovascular events, except for increased stroke/TIA in females (HR 1.744 [1.654-1.839]). Compared with GLP1RA, SGLT2i use was associated with a decrease risk of MACE in both men and women, but higher risk for other cardiovascular and peripheral vascular events. Among SGLT2i users, those who developed erythrocytosis had increased incidence of thromboembolic events compared to those without erythrocytosis. Lastly, among SGLT2i patients treated for their erythrocytosis, the men who discontinued SGLT2i had increased risks of stroke/TIA, MI, and limb ischemia, while women had increased risk of stroke/TIA, MI, and venous thrombosis. Those who received anti-platelet therapy were associated with elevated risks of stroke/TIA, MI, venous thrombosis, and limb ischemia. In contrast, patients who receive phlebotomy had no significant difference in the outcomes. Therefore, regular monitoring of hematologic parameters is recommended for early detection and modified therapeutic strategies should be considered to reduce complication risks.
5 Likes